RT Journal Article
T1 Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients
A1 Blanquez-Martinez, David
A1 Diaz-Villamarin, Xando
A1 Antunez-Rodriguez, Alba
A1 Pozo-Agundo, Ana
A1 Munoz-avila, Jose Ignacio
A1 Martinez-Gonzalez, Luis Javier
A1 Davila-Fajardo, Cristina Lucia
K1 myopia
K1 pharmacogenetic
K1 genetic polymorphism
K1 personalized medicine
K1 ranibizumab
K1 anti-VEGF
K1 VEGFA
K1 CFH
K1 ARMS2
K1 Subfoveal choroidal neovascularization
K1 Complement factor-h
K1 Randomized clinical-trial
K1 Anti-vegf treatment
K1 Macular degeneration
K1 Pathological myopia
K1 Intravitreal ranibizumab
K1 Photodynamic therapy
K1 Visual prognosis
K1 Age
AB High myopia is an ophthalmic pathology that affects half of the young adults in the United States and Europe and it is predicted that a third of the world's population could be nearsighted at the end of this decade. It is characterized by at least 6 diopters or axial length > 26 mm and, choroidal neovascularization (CNV) in 5 to 11% of cases. Ranibizumab is a recombinant humanized monoclonal antibody fragment. It is an anti-vascular endothelial growth factor (anti-VEGF) drug used in the treatment of CNV. Many genetic polymorphisms have been associated with interindividual differences in the response to ranibizumab, but these associations were not yet assessed among patients with high myopia and CNV. We performed a retrospective study assessing the association of genetic polymorphisms with response to ranibizumab in patients with CNV secondary to high myopia (mCNV). We included genetic polymorphisms previously associated with the response to drugs used in CNV patients (bevacizumab, ranibizumab, aflibercept, and photodynamic therapy (PDT)). We also included genetic variants in the VEGFA gene. Based on our results, ARMS2 (rs10490924) and CFH (rs1061170) are associated with response to ranibizumab in high myopia patients; and, included VEGFA genetic polymorphisms are not associated with ranibizumab response in our population but might be related to a higher risk of CNV.
PB Mdpi
YR 2021
FD 2021-11-01
LK https://hdl.handle.net/10668/26383
UL https://hdl.handle.net/10668/26383
LA en
DS RISalud
RD Apr 7, 2025